AminoVault AI Market Strategy Report - Peptide Suppliers

Answer Capsule

AminoVault holds 11.14% valid recommendation coverage in the September 2026 LLM Authority Index peptide suppliers benchmark, ranking fourth of seven tracked brands. The company is visible in 19.14% of qualified AI answers but converts that presence into a valid recommendation less often than the category leader, Phoenix Pharmaceuticals, which holds 18.57% coverage. AminoVault's clearest strength is first-position quality: its 5.71% rank-one rate is the highest in the category, ahead of Phoenix Pharmaceuticals at 3.14%, even as AminoVault appears in roughly one in five answers while the leader appears in nearly three in five. The clearest opportunity is expanding recommendation coverage across the consideration cluster without losing the rank-one efficiency it already holds.

Who This Report Is For

This report is written for AminoVault's commercial, brand, and growth leadership, and for category buyers and analysts tracking how peptide suppliers are recommended across AI and search surfaces.

Report Card

Executive Summary

AminoVault enters September 2026 as a visible but under-scaled brand in AI-generated peptide supplier recommendations. The benchmark recorded 67 mentions across 350 qualified observations, a raw mention presence rate of 19.14%, but only 39 of those observations converted into a valid recommendation, a coverage rate of 11.14%. That places AminoVault fourth in the category by recommendation coverage, behind Phoenix Pharmaceuticals at 18.57%, Core Peptides at 15.14%, and Biotech Peptides at 13.14%.

The framing quality around AminoVault is strong. Of its 67 mentions, 58 were positive, 9 were neutral, and none were negative, producing a net sentiment score of 0.8657, the second highest in the tracked set behind Blue Sky Peptide's 0.92. The benchmark shows no cautionary or negative framing attached to the brand in the September qualified set.

AminoVault's most distinctive signal is placement quality. Its 5.71% rank-one rate is the highest in the category, and its average recommended rank of 2.03 is the best among all tracked brands. When AI systems do recommend AminoVault, they tend to place it first or near first. Phoenix Pharmaceuticals, by contrast, holds nearly double the recommendation coverage but converts that into a rank-one placement only 3.14% of the time, with an average recommended rank of 2.64.

The gap sits in coverage breadth, not in recommendation strength. AminoVault appears in 19.14% of qualified observations while Phoenix Pharmaceuticals appears in 59.71%. The benchmark's own placement snapshot makes this explicit: similar coverage levels can hide very different first-position rates, and AminoVault's 11.14% coverage paired with a 5.71% rank-one rate is a more efficient recommendation profile than the leader's 18.57% coverage paired with 3.14%.

The strongest platform signal for AminoVault is Google AI Overviews, where the brand recorded a 17.00% valid recommendation coverage rate, a 15.00% rank-one rate, and a perfect 1.0 sentiment score across 28 mentions. Google AI Mode follows at 14.02% coverage with a 4.67% rank-one rate. The clearest platform gap is Gemini, where AminoVault recorded a single valid recommendation across 69 observations, a 1.45% coverage rate, and no rank-one placements.

The benchmark's month-over-month record adds context. AminoVault's coverage held within normal variation across the full series, down 0.9 points from 12.0% in July 2026 to 11.1% in September 2026, but the September figure followed an 8.7 point single-month decline from 19.8% in August 2026. The August surge was not sustained. The question for AminoVault is whether the lower September level is the new baseline or a pause before the brand rebuilds toward its August peak.

What AminoVault Is Winning

Questions This Section Answers

• Which dimension of AI recommendation does AminoVault lead the peptide supplier category on?
• How does AminoVault's Google AI Overviews performance compare to its other surfaces?

AminoVault holds the strongest first-position profile in the peptide suppliers category. Its 5.71% rank-one rate is the highest of any tracked brand, and its average recommended rank of 2.03 is the best in the set. When AI systems name AminoVault, they tend to name it first.

The brand also carries the cleanest framing in the category after Blue Sky Peptide. With 58 positive mentions, 9 neutral, and zero negative across 350 qualified observations, AminoVault's net sentiment score of 0.8657 reflects a public evidence layer that is not generating cautionary or comparison-anchor framing.

Google AI Overviews is AminoVault's strongest platform by a wide margin. The brand recorded 17 valid recommendations across 100 platform observations, a 17.00% coverage rate, and 15 rank-one placements, a 15.00% rank-one rate. That is the highest rank-one rate any tracked brand achieved on any single platform in the September set.

AminoVault also holds a narrow but meaningful recommendation pocket in the consideration cluster. Its 8.29% top-three rate and 5.71% rank-one rate in the "Best Research Peptide Companies & Sources" cluster place it ahead of Core Peptides and Biotech Peptides on first-position quality, even though both brands hold higher overall coverage.

Where AminoVault Has the Clearest AI Visibility Gaps

Questions This Section Answers

• Why is recommendation coverage scale the primary constraint on AminoVault's volume?
• What happened to AminoVault's Gemini presence between visibility and recommendation credit?
• What caused the August-to-September coverage retracement from 19.8% to 11.1%?

The clearest gap is coverage scale. AminoVault appears in 19.14% of qualified observations, but Phoenix Pharmaceuticals appears in 59.71%. The leader is mentioned in roughly three of every five AI answers in the category, while AminoVault is mentioned in roughly one in five. That presence gap is the primary constraint on recommendation volume.

The second gap is recommendation conversion on Gemini. AminoVault recorded 7 mentions across 69 Gemini observations, a 10.14% presence rate, but only 1 valid recommendation, a 1.45% coverage rate, and zero rank-one placements. Phoenix Pharmaceuticals, by contrast, recorded an 84.06% presence rate on Gemini with 58 mentions, though it also converted none of those into rank-one placements. The Gemini surface is producing visibility for AminoVault without producing recommendation credit.

The third gap is the absence of qualified observations in the evaluation and decision clusters. The benchmark's "Peptide Supplier & Product Comparisons" and "Research Peptide Pricing & Where to Buy" clusters each contained zero qualified observations in September 2026. AminoVault's recommendation profile is therefore measured entirely within the consideration-stage "Best Research Peptide Companies & Sources" cluster. The brand's position in comparison and pricing-stage AI answers is not yet visible in the public benchmark.

The fourth gap is the August-to-September retracement. AminoVault's coverage fell 8.7 points from 19.8% in August 2026 to 11.1% in September 2026, a significant single-month decline that erased most of its prior gain. Valid recommendation count fell from 66 in August to 39 in September. The benchmark identifies this as a retracement rather than a trend, but the drivers behind the August peak were not sustained.

Biggest Opportunity

Questions This Section Answers

• How can AminoVault expand recommendation coverage without losing its rank-one efficiency?
• Which recommendation prompts is AminoVault currently thinnest on relative to Phoenix Pharmaceuticals?

The single largest opportunity is expanding AminoVault's recommendation coverage in the consideration cluster while protecting its rank-one efficiency. The brand already converts a higher share of its recommendations into first-position placements than any competitor. The constraint is not recommendation quality, it is recommendation volume. Closing even part of the 40-point presence gap to Phoenix Pharmaceuticals would translate directly into additional valid recommendations at the category's best conversion rate.

The prompt evidence points to where that expansion should start. The consideration cluster prompts that produced qualified observations include "best place to buy peptides online," "where to buy peptides," "best peptide company," and "What is the best peptide company to buy from?" These are direct recommendation queries where AminoVault's first-position strength is most valuable and where the brand's presence is currently thinnest relative to the leader.

Competitive Landscape

Questions This Section Answers

• How does AminoVault's first-position profile compare to Phoenix Pharmaceuticals' coverage advantage?
• Which peptide suppliers lead on top-three rate, rank-one rate, and average recommended rank?

Phoenix Pharmaceuticals holds the strongest recommendation-stage position in the peptide suppliers category by coverage, but AminoVault holds the strongest first-position profile. The two brands are winning on different dimensions: Phoenix Pharmaceuticals on breadth of presence, AminoVault on placement quality when it is named.

Average recommended rank covers rank-eligible recommendations only.

AminoVault sits third by top-three rate but first by rank-one rate and first by average recommended rank. The table shows a brand that is recommended less often than the two brands above it but placed higher when it is recommended.

Prompt Evidence

Google AI Overviews / Best Research Peptide Companies & Sources Prompt: "best place to buy peptides online" Result: AminoVault recorded its strongest platform performance here, with 17 valid recommendations and 15 rank-one placements across 100 AI Overviews observations.

Gemini / Best Research Peptide Companies & Sources Prompt: "best peptide company" Result: AminoVault appeared in 7 of 69 Gemini observations but converted only 1 into a valid recommendation, with no rank-one placements on this surface.

Google AI Mode / Best Research Peptide Companies & Sources Prompt: "What is the best peptide company to buy from?" Result: AminoVault recorded 15 valid recommendations and 5 rank-one placements across 107 AI Mode observations, a 14.02% coverage rate.

Copilot / Best Research Peptide Companies & Sources Prompt: "where to buy peptides" Result: AminoVault appeared in 6 of 46 Copilot observations with 4 valid recommendations, all ranked outside the top three, with an average recommended rank of 5.

What CiteWorks Studio Would Do Next

Phase 1: AI Market Discovery Audit Map AminoVault's prompt-level recommendation profile across all six surfaces, isolating which consideration-cluster prompts produce rank-one placements and which produce presence without recommendation credit.

Phase 2: Recommendation Readiness Plan Prioritize the Gemini and Copilot gaps, where AminoVault is visible but under-recommended, and define the evidence and framing changes needed to convert presence into shortlist placement.

Phase 3: Owned Answer Layer Buildout Strengthen the owned pages that AI systems retrieve for direct recommendation queries, with clear positioning on supplier identity, product range, and category fit.

Phase 4: Citation / Authority Layer Development Build the third-party source footprint that AI systems appear to synthesize from, focusing on the source types already surfacing AminoVault in Google AI Overviews and AI Mode.

Phase 5: Monthly AI Visibility and Recommendation Tracking Track coverage, top-three rate, rank-one rate, and sentiment month over month to confirm whether the September level is a new baseline or a pause before recovery.

Why This Matters

AminoVault's position in the September 2026 benchmark is a buyer-choice problem, not a visibility problem. The brand is mentioned in roughly one in five AI answers and carries the best first-position rate in the category, but it is named far less often than the leader. In a category where no brand exceeded 18.57% recommendation coverage and three brands declined significantly across the series, the brands that expand their presence in direct recommendation queries will capture the shortlist positions that are currently going to Phoenix Pharmaceuticals by default.

AI presence alone is not enough, and AminoVault's own data shows why. The brand's Gemini profile is the clearest example: 7 mentions, 1 valid recommendation, zero rank-one placements. Visibility without recommendation conversion does not move a buyer. The next move is targeted correction of the prompt, page, and citation layers that determine whether AminoVault is named, and named first, when a buyer asks an AI system for a peptide supplier recommendation.

Core Metrics

Sentiment Score

Questions This Section Answers

• How is AminoVault's net sentiment score of 0.8657 calculated from its mention classifications?
• Why is classified sentiment a better diagnostic than raw mention counts for interpreting AI visibility?

Sentiment Score = (positive mentions × 1 + neutral mentions × 0 + negative mentions × -1) / total mentions

For AminoVault in September 2026: (58 × 1 + 9 × 0 + 0 × -1) / 67 = 0.8657.

This matters because unclassified mention counts are misleading. A brand with 67 mentions and a 0.87 sentiment score is in a very different position from a brand with 67 mentions and a 0.40 score, even though both would report the same raw presence. Share of voice is a diagnostic metric, not a business KPI. A positive recommendation, a neutral reference, a cautionary mention, and a competitor-displaced mention are not equal, and counting all mentions as wins is bad measurement. Classified sentiment is required before interpreting AI visibility, because it separates brands that AI systems actively recommend from brands that AI systems merely name.

AminoVault's 0.8657 score reflects a public evidence layer that is generating positive framing without cautionary or negative counterweight. That is a strong position, but it does not by itself produce recommendation volume. The brand's constraint is coverage, not framing quality.

Sentiment by Platform

Methodology

1. This report is a benchmark-based analysis of AminoVault's position in the LLM Authority Index AI Market Discovery Index for the peptide suppliers vertical. It is not a client implementation case study.
2. The reporting month is September 2026, with comparison points from July 2026 and August 2026 where the benchmark provides them.
3. Six AI surface families were tracked: ChatGPT, Copilot, Gemini, Perplexity, Google AI Overviews, and Google AI Mode. All six produced qualified observations in September 2026.
4. The September 2026 benchmark began with 530 prompt-surface observations across 349 unique questions. Of these, 469 were relevant to the peptide suppliers category and 61 were irrelevant, producing 350 qualified observations as the public denominator.
5. Seven brands were tracked: AminoVault, Biotech Peptides, Blue Sky Peptide, Core Peptides, Peptide Tech, Peptides Source, and Phoenix Pharmaceuticals.
6. One high-intent cluster produced qualified observations in September 2026: "Best Research Peptide Companies & Sources," a consideration-stage cluster. The benchmark defines two additional clusters, "Peptide Supplier & Product Comparisons" and "Research Peptide Pricing & Where to Buy," but both contained zero qualified observations in the September set.
7. Stage 0 extraction produced the prompt-level observations that retain the query, AI surface, answer, brand outcome, recommendation placement, sentiment, and, where exposed, citations or attributable evidence sources.
8. A mention is counted when AminoVault appears in a qualified AI answer, regardless of recommendation status. Presence rate is the share of qualified observations in which the brand is mentioned at all.
9. A valid recommendation is counted when AminoVault receives an explicit recommendation or shortlist placement in a qualified answer. Neutral, cautionary, comparison-anchor, and listed-only mentions are not counted as valid recommendations.
10. Top-three rate and rank-one rate are calculated against the 350 qualified observations. Average recommended rank covers rank-eligible recommendations only.
11. The benchmark's public series measures brand recommendation discovery specifically. It does not yet contain qualified observations in pricing or multi-brand comparison queries, so this report cannot speak to AminoVault's position in those buyer-intent classes.
12. Small counts warrant caution. AminoVault's per-platform figures, particularly on ChatGPT, Copilot, and Perplexity, rest on small samples and should be read as directional rather than definitive.

See How AI Is Recommending Your Brand

The public benchmark shows where AminoVault stands in AI-generated peptide supplier recommendations. A company-level AI visibility audit maps the prompt, surface, competitor, ranking, sentiment, and evidence-source patterns behind those numbers into a prioritized strategy. It moves from what changed to why it changed, and from category-wide movement to brand-specific diagnosis.